Thomas F Jaki (T Jaki, Thomas Jaki)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 54

Top Venues

Statistics in medicine

Pharmaceutical statistics

Statistical methods in medical research

Nature communications

University of Cambridge

University of South Carolina, Columbia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Cambridge Apr 20 2020

United Kingdom

Programme Leader DART :: MRC Biostatistics Unit

Lancaster University Jun 01 2008

United Kingdom

Professor of Statistics :: Mathematics and Statistics

Education History

University of South Carolina, Columbia Aug 15 2003 - Aug 15 2006

United States

PHD :: Statistics

Publications

Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research (2024)
Thomas Burnett, Franz Koenig, Thomas F Jaki
Adding experimental treatment arms to multi-arm multi-stage platform trials in progress. Statistics in medicine (2024)
Amin Yarahmadi, Lori E Dodd, Thomas F Jaki, Peter W Horby, Nigel Stallard
Group sequential designs for clinical trials when the maximum sample size is uncertain. Statistics in medicine (2024)
Peter Greenstreet, Thomas F Jaki, Alun Bedding, Chris Harbron, Pavel Mozgunov
A multi-arm multistage platform design that allows preplanned addition of arms while still controlling the family-wise error. Statistics in medicine (2024)
null null, Peter W Horby, Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A Green, Devesh J Dhasmana, Flora Malein, Jaydip Majumdar, Paul J Collini, Jack Shurmer, Bryan Yates, John Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas F Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn M Rowan, Guy E Thwaites, Richard Haynes, Martin J Landray
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature communications 15 (1) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
Alena Kuhlemeier, Thomas F Jaki, Katie Witkiewitz, Elizabeth A Stuart, M Lee Van Horn
Validation of predicted individual treatment effects in out of sample respondents. Statistics in medicine (2024)
null null, Peter W Horby, Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A Green, Devesh J Dhasmana, Flora Malein, Jaydip Majumdar, Paul J Collini, Jack Shurmer, Bryan Yates, John Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas F Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn M Rowan, Guy E Thwaites, Richard Haynes, Martin J Landray
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature communications 15 (1) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
null null, Peter W Horby, Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A Green, Devesh J Dhasmana, Flora Malein, Jaydip Majumdar, Paul J Collini, Jack Shurmer, Bryan Yates, John Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas F Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn M Rowan, Guy E Thwaites, Richard Haynes, Martin J Landray
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature communications 15 (1) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
null null, Peter W Horby, Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A Green, Devesh J Dhasmana, Flora Malein, Jaydip Majumdar, Paul J Collini, Jack Shurmer, Bryan Yates, John Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas F Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn M Rowan, Guy E Thwaites, Richard Haynes, Martin J Landray
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature communications 15 (1) (2024)
Thomas Burnett, Franz Koenig, Thomas F Jaki
Adding experimental treatment arms to multi-arm multi-stage platform trials in progress. Statistics in medicine 43 (18) (2024)
Peter Greenstreet, Thomas F Jaki, Alun Bedding, Chris Harbron, Pavel Mozgunov
A multi-arm multi-stage platform design that allows preplanned addition of arms while still controlling the family-wise error. Statistics in medicine 43 (19) (2024)
Helen Yvette Barnett, Matthew George, Donia Skanji, Gaelle Saint-Hilary, Thomas F Jaki, Pavel Mozgunov
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies. Statistical methods in medical research 33 (2) (2024)
null null, Peter W Horby, Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A Green, Devesh J Dhasmana, Flora Malein, Jaydip Majumdar, Paul J Collini, Jack Shurmer, Bryan Yates, John Kenneth Baillie, Maya H Buch, Jeremy N Day, Saul N Faust, Thomas F Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn M Rowan, Guy E Thwaites, Richard Haynes, Martin J Landray
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature communications 15 (1) (2024)
Varsha Ramineni, Philip Millroth, Lalitha Iyadurai, Thomas F Jaki, Jonathan Kingslake, Julie Highfield, Charlotte Summers, Michael B Bonsall, Emily A Holmes
Treating intrusive memories after trauma in healthcare workers: a Bayesian adaptive randomised trial developing an imagery-competing task intervention. Molecular psychiatry (2023)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki
A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering. Statistics in medicine (2023)
David S Robertson, Babak Choodari-Oskooei, Munyaradzi Dimairo, Laura Flight, Philip Pallmann, Thomas F Jaki
Point estimation for adaptive trial designs II: Practical considerations and guidance. Statistics in medicine (2023)
Varsha Ramineni, Philip Millroth, Lalitha Iyadurai, Thomas F Jaki, Jonathan Kingslake, Julie Highfield, Charlotte Summers, Michael B Bonsall, Emily A Holmes
Treating intrusive memories after trauma in healthcare workers: a Bayesian adaptive randomised trial developing an imagery-competing task intervention. Molecular psychiatry (2023)
Christina Yap, Olga Solovyeva, Johann S de Bono, Jan Rekowski, Dhrusti Patel, Thomas F Jaki, Adrian P Mander, Thomas R Jeffry Evans, Richard Wilson Peck, Kathryn S Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Jane Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Dudley Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P Richards, Oliver Boix, James Matcham, Lesley Seymour, Susan Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan D Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J Weir
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ (Clinical research ed.) 383 (2023)
David S Robertson, James M S Wason, Franz Koenig, Martin Posch, Thomas F Jaki
Online error rate control for platform trials. Statistics in medicine (2023)
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J Weir, An-Wen Chan, Thomas F Jaki, Adrian P Mander, Thomas R Jeffry Evans, Richard Wilson Peck, Kathryn S Hayward, Melanie Jane Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Dudley Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P Richards, Oliver Boix, James Matcham, Lesley Seymour, Susan Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan D Berlin, Aude Espinasse, Johann S de Bono
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ (Clinical research ed.) 383 (2023)
Olga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas F Jaki, Adrian P Mander, Thomas R Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn P Richards, Lesley Roberts, John Kirkpatrick, Johann S de Bono, Christina Yap
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC medicine 21 (1) (2023)
Libby Daniells, Pavel Mozgunov, Alun Bedding, Thomas F Jaki
A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method. Statistics in medicine (2023)
Helen Yvette Barnett, Oliver Boix, Dimitris Kontos, Thomas F Jaki
Backfilling cohorts in phase I dose-escalation studies. Clinical trials (London, England) (2023)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki
A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering. Statistics in medicine (2023)
Emily Graham, Chris Harbron, Thomas F Jaki
Updating the probability of study success for combination therapies using related combination study data. Statistical methods in medical research (2023)
Helen Yvette Barnett, Oliver Boix, Dimitris Kontos, Thomas F Jaki
Dose finding studies for therapies with late-onset toxicities: A comparison study of designs. Statistics in medicine (2022)
James M S Wason, Munyaradzi Dimairo, Katie Biggs, Sarah Bowden, Julia M Brown, Laura Flight, Jamie Hall, Thomas F Jaki, Rachel Lowe, Philip Pallmann, Mark A Pilling, Claire Snowdon, Matthew Robert Sydes, Sofía S Villar, Christopher J Weir, Nina Wilson, Christina Yap, Helen C Hancock, Rebecca H Maier
Practical guidance for planning resources required to support publicly-funded adaptive clinical trials. BMC medicine 20 (1) (2022)
David S Robertson, Babak Choodari-Oskooei, Munyaradzi Dimairo, Laura Flight, Philip Pallmann, Thomas F Jaki
Point estimation for adaptive trial designs I: A methodological review. Statistics in medicine (2022)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki
An order restricted multi-arm multi-stage clinical trial design. Statistics in medicine 41 (9) (2022)
Alessandra Serra, Pavel Mozgunov, Thomas F Jaki, Fabio Rigat
What is the expected benefit of patient-centric clinical development in oncology? Journal of biopharmaceutical statistics 32 (3) (2022)
Pavel Mozgunov, Thomas F Jaki, Ioannis Gounaris, Thomas Goddemeier, Anja Victor, Marianna Grinberg
Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial. Statistics in medicine (2022)
Alena Kuhlemeier, Yasin Desai, Alexandra Tonigan, Katie Witkiewitz, Thomas F Jaki, Yu-Yu Hsiao, Chi Chang, M Lee Van Horn
Applying methods for personalized medicine to the treatment of alcohol use disorder. Journal of consulting and clinical psychology 89 (4) (2021)
H Jackson, S Bowen, Thomas F Jaki
Using biomarkers to allocate patients in a response-adaptive clinical trial. Communications in statistics: Simulation and computation 52 (12) (2021)
Nicolás M Ballarini, Thomas Burnett, Thomas F Jaki, Christopher Jennison, Franz Koenig, Martin Posch
Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. Statistics in medicine 40 (12) (2021)
Pavel Mozgunov, Suzie Cro, Anne Lingford-Hughes, Louise M Paterson, Thomas F Jaki
A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial. Pharmaceutical statistics (2021)
Pavel Mozgunov, Rochelle Knight, Helen Barnett, Thomas F Jaki
Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study. International journal of environmental research and public health 18 (1) (2021)
Nicolás M Ballarini, Yi-Da Chiu, Franz Koenig, Martin Posch, Thomas F Jaki
A critical review of graphics for subgroup analyses in clinical trials. Pharmaceutical statistics 19 (5) (2020)
Lori E Dodd, Dean A Follmann, Jing Wang, Franz Koenig, Lisa L Korn, Christian Schoergenhofer, Michael Proschan, Sally Hunsberger, Tyler Bonnett, Mat Makowski, Drifa Belhadi, Yeming Wang, Bin Cao, France Mentre, Thomas F Jaki
Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical trials (London, England) 17 (5) (2020)
Martin J Wolfsegger, Alexander Bauer, Detlew Labes, Helmut Schütz, Richardus Vonk, Benjamin Lang, Stephan Lehr, Thomas F Jaki, Werner Engl, Michael D Hale
Assessing goodness-of-fit for evaluation of dose-proportionality. Pharmaceutical statistics 20 (2) (2020)
Nigel Stallard, Lisa Hampson, Norbert Benda, Werner Brannath, Thomas Burnett, Tim Friede, Peter K Kimani, Franz Koenig, Johannes Krisam, Pavel Mozgunov, Martin Posch, James M S Wason, Gernot Wassmer, John Whitehead, S Faye Williamson, Sarah Zohar, Thomas F Jaki
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in biopharmaceutical research 12 (4) (2020)
Fabiola La Gamba, Tom Jacobs, Helena Geys, Thomas F Jaki, Jan Serroyen, Moreno Ursino, Alberto Russu, Christel Faes
Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned. Pharmaceutical statistics 18 (4) (2019)
Philip Pallmann, Fang Wan, Adrian P Mander, Graham M Wheeler, Christina Yap, Sally Clive, Lisa V Hampson, Thomas F Jaki
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical trials (London, England) 17 (2) (2019)
Thomas F Jaki, Allan Gordon, Pamela Forster, Luc Bijnens, Bjoern Bornkamp, Werner Brannath, Roberto Fontana, Mauro Gasparini, Lisa V Hampson, Tom Jacobs, Byron Jones, Xavier Paoletti, Martin Posch, Andrew Titman, Richardus Vonk, Franz Koenig
Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873. Pharmaceutical statistics 18 (3) (2019)
Pavel Mozgunov, Thomas F Jaki, Xavier Paoletti
Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. Journal of biopharmaceutical statistics 29 (2) (2018)
Amy Cotterill, Thomas F Jaki
Dose-escalation strategies which use subgroup information. Pharmaceutical statistics 17 (5) (2018)
Thomas F Jaki, A Gordon, P Forster, L Bijnens, B Bornkamp, Werner Brannath, R Fontana, M Gasparini, L V Hampson, T Jacobs, B Jones, X Paoletti, M Posch, A Titman, R Vonk, Franz Koenig
A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical statistics 17 (5) (2018)
Philip Pallmann, Thomas F Jaki
Simultaneous confidence regions for multivariate bioequivalence. Statistics in medicine 36 (29) (2017)
Eleni Vradi, Werner Brannath, Thomas F Jaki, Richardus Vonk
Model selection based on combined penalties for biomarker identification. Journal of biopharmaceutical statistics 28 (4) (2017)
Wai Yin Yeung, Bruno Reigner, Ulrich Beyer, Cheikh Diack, Daniel Sabanés Bové, Giuseppe Palermo, Thomas F Jaki
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy. Pharmaceutical statistics 16 (6) (2017)
Lisa V Hampson, Roland Fisch, Linh M Van, Thomas F Jaki
Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children. Statistics in medicine 36 (3) (2016)
Thomas F Jaki, Alice Parry
Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims. Pharmaceutical statistics 15 (4) (2016)
Thomas F Jaki, Lisa V Hampson
Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection. Statistics in medicine 35 (4) (2015)

Thomas F Jaki.css-eqlu8i{font-size:small;padding-left:4px;} (T Jaki, Thomas Jaki)

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas F Jaki (T Jaki, Thomas Jaki)